A number of studies over the past decade have supported the role of TGF-␤ as an important pathologic factor in excessive scar formation, 10 -18 making it a potential drug target for scar reduction therapy. 10, 11 Neutralizing antibodies to TGF-␤1 and TGF-␤2 have been shown to decrease scarring in adult rat incisional wounds. 19 Other approaches used to antagonize TGF-␤-stimulated fibrosis include the use of the TGF-␤-binding proteoglycan decorin 20 and mannose-6-phosphate, an inhibitor of TGF-␤ activation. 21 At least three different receptors (types 1, 2, and 3) are involved in TGF-␤ signaling. Whereas TGF-␤ receptors 1 and 2 appear to be signaling receptors, the type 3 receptor presents ligands to receptors 1 and 2 for phosphorylation. 22, 23 This phosphorylation activates TGF-␤ receptor kinase activity and promotes its interactions with downstream effector molecules, including members of the Smad family. 22, 23 Smad proteins, the first substrates of TGF-␤ receptor 1 to be identified, play a central role in the transduction of receptor signals to target genes in the nucleus. The subfamily Smad2 and its close homolog Smad3, known as receptor Smads (R-Smads) are activated primarily by TGF-␤ and its receptors. 22, 23 Once activated by TGF-␤ receptors, heteromeric Smad2/Smad3 oligomerizes with Smad4 (also known as co-Smad). The hetero-oligomeric Smad2-Smad3-Smad4 complex subsequently translocates from the cytoplasm into the nucleus, where it activates target gene transcription in association with DNA-binding partners. 22, 23 The role of Smad proteins in wound healing and keloid scar formation recently has been demonstrated. Mice lacking Smad3 have shown accelerated wound healing and reduced local inflammatory response. 24, 25 The important roles and mechanisms of Smad3 in collagen type 1 gene expression and syntheses also have been elucidated, suggesting its involvement in pathologic fibrosis. 26 -33 It has been proposed that suppression of the Smad regulatory mechanism could contribute to aberrant TGF-␤ responses underlying pathologic fibrosis. 29, 33, 34 Quercetin is the most common of the flavonoid glycones found in the diet. 35, 36 The richest sources of quercetin are onions, apples, and red wine. 37 Quercetin also is identified as an active ingredient of medicinal plants such as the ginkgo biloba. 36 Human consumption is estimated to be approxi-mately 4 to 68 mg per day. 35, 38 Quercetin has a wide range of biologic activity including antiviral, antiinflammatory, and antimicrobial properties. Quercetin causes cell cycle arrest in human leukemic T cells as well as human breast, ovarian, and gastric cancer cells. 39, 40 Quercetin also induces apoptosis through a pathway involving heat shock proteins 41 and downregulates the mutant p53 gene. 36 Results from previous studies have demonstrated that quercetin exhibits strong inhibitory effects on keloid fibroblast proliferation and collagen production and suppresses the insulin-like growth factor-1 (IGF-1)-signaling pathway. 42, 43 On the basis of these results, the authors hypothesized that quercetin may have an inhibitory effect on TGF-␤/Smad signaling. To pursue this hypothesis, they investigated the effect of quercetin on TGF-␤ receptors 1 and 2 (TGF-␤R1 and TGF-␤R2) as well as Smad protein expression and function in keloid-derived fibroblasts. The inhibition of TGF-␤R1, TGF-␤2, and the function of Smad protein signaling in keloid-derived fibroblasts treated with quercetin suggested a molecular mechanism for the work of this compound to suppress proliferation and collagen production of keloid-derived fibroblasts.
MATERIALS AND METHODS

Media and Chemicals
Dulbecco's Modified Eagle's Medium (DMEM), fetal calf serum (FCS), Hank's balanced salt solution, streptomycin, penicillin, gentamycin, and fungizone were supplied by Invitrogen (Carlsbad, CA). Quercetin was purchased from Sigma Chemical Company (St. Louis, MO).
Rabbit anti-TGF-␤R1 and anti-TGF-␤R2 antibodies, rabbit polyclonal anti-Smad3, mouse anti-Smad4, mouse monoclonal anti-CBP, and rabbit polyclonal anti-p300 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-Smad2/3 antibodies were supplied by BD Transduction Laboratories (San Jose, CA). Rabbit anti-phospho-Smad2 antibodies were obtained from Upstate Biotechnology (Lake Placid, NY), and mMouse monoclonal anti-phosphoserine antibody was supplied by Calbiochem (San Diego, CA).
Excessive Scar-Derived Fibroblast Selection
Fibroblasts from a specimen collection of earlobe keloid scar samples were selected. None of the patients had received previous treatment for the keloids before surgical excision. Before the excision, a full history was taken and an examination was performed, complete with color slide photodocumentation and informed consent.
Fibroblast Culture From Earlobe Keloids
Fibroblasts were isolated from earlobe keloid scars using the explant technique. Cells were pelleted and grown in tissue culture flasks. Fibroblast cell strains were maintained in DMEM containing 10% (v/v) fetal bovine serum and stored at Ϫ150°C until use. Only cells from the second passage were 
Western Blotting and Immunoprecipitation
Cultured fibroblasts under different experimental conditions were lysed in lysis buffer (1 mmol/L CaCl2, 1 mmol/L MgCl2, 1% [v/v] NP-40, 1 g/mL leupeptin, 1 g/mL aprotinin, 1 mol/L PMSF, and 100 mol/L NaVO 4 ). Proteins were subjected to Western blot analysis as described. 44 To investigate the effects of quercetin on expression of TGF-␤R1, TGF-␤R2, Smad2, Smad3, Smad4, phospho-Smad2, CBP, and p300, 50-g total protein extract was separated by 8% or 6% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and electroblotted onto nitrocellulose membrane. Blots were incubated with the specific antibodies against TGF-␤R1 and TGF-␤R2, Smad2, Smad3, Smad4, phospho-Smad2, CBP, and p300 as well as horseradish peroxidase-conjugated donkey antimouse or antirabbit secondary antibody (1:7,500). Blots were visualized with a chemiluminescent detection system (ECL; Amersham Bioscience, New Jersey), as described by the manufacturer.
To investigate the effects of quercetin on the formation of the Smad2-Smad3-Smad4 complex, 2 mg of whole-cell lysate of keloid fibroblasts treated with or without quercetin were immunoprecipitated overnight at 4°C with 6 g of anti-Smad3, followed by precipitation with 100 L of protein G-sepharose for 90 minutes at 4°C. After four washes with complete lysis buffer, the immunoprecipitates were eluted by boiling for 5 minutes in 100 L of ϫ2 loading dye. The resulting immunoprecipitates were electrophoresed through an 8% SDS-PAGE gel, transferred onto a polyvinylidene difluoride membrane, and immunoblotted with anti-Smad3, antiphosphoserine, anti-phospho-Smad2, and anti-Smad4. The blots were developed with chemiluminescence reagents. Qualification of the bands on autoradiograms was performed using densitometric analysis.
RESULTS
The effect of quercetin on TGF-␤R1 and TGF-␤R2 expression of keloid fibroblasts was first investigated. Significant reduction of both TGF-␤R1 and TGF-␤R2 expression was observed in keloid fibroblasts treated with quercetin. This reduced expression was obvious at day 3 after quercetin treatment (Fig. 1) . The three different concentrations of the
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The effect of quercetin on expression of Smad2, Smad3, and Smad4 by keloid fibroblasts also was investigated. Quercetin strongly suppressed the expression of Smad2, Smad3, and Smad4, and also reduced phosphorylated Smad2 and Smad3 in keloid fibroblasts (Figs. 2 and 3 ). Significant downregulation of these proteins was maximal after 72 hours of incubation with quercetin (Fig. 2) . Although similar levels of inhibition were seen with all three concentrations of quercetin, a concentration of 20 g/mL appeared to have the strongest inhibitory effect (Fig. 2) .
To investigate the inhibitory effect of quercetin on the formation of the Smad2-Smad3-Smad4 complex, total cell lysates of keloid fibroblasts with or without quercetin at 5 g/mL were immunoprecipitated with anti-Smad3 antibody. The resulting complexes were electrophoresed, followed by Western blotting with anti-phospho-Smad2 and anti-Smad4 antibodies. No expression of phospho-Smad2 or phosphoSmad4 was seen in keloid fibroblasts treated with quercetin ( Fig. 3) , indicating a blocking effect of the compound on the formation of the Smad2-Smad3-Smad4 complex.
Transcriptional coactivators p300 and CBP play a critical role in the stimulation of endogenous type 1 collagen gene expression, and enhance Smad-dependent stimulation of COLA1A2 promoter activity in human dermal fibroblasts, leading to overproduction of collagen and fibrosis. 31 The effect of quercetin on protein expression of CBP and p300 was investigated. The data in Figure 4 show that both CBP and p300 levels were suppressed by quercetin at 5 g/mL, indicating another potential mechanism of action whereby quercetin may inhibit collagen production in keloid fibroblasts. 
Fig. 1. Effect of quercetin on protein expression of transforming growth factor beta (TGF␤) receptors 1 and 2. Keloid fibroblasts were cultured and incubated with medium containing 10% fetal calf serum in the absence or presence of the indicated concentrations of quercetin for 72 hours. Cells then were harvested and lysed for Western blot analysis by hybridizing with polyclonal anti-TGF␤ R1 and anti-TGF␤ R2 antibodies. The expression of TGF-␤R1 and TGF-␤R2 was reduced by quercetin treatment. The level of inhibition was similar at all three concentrations.
Fig. 2. Effect of quercetin on protein expression of
DISCUSSION
It is known that TGF-␤ signaling plays a fundamental role in pathologic fibroproliferation and abnormal scar formation. It has been hypothesized that TGF-␤ stimulates the transcription of the ␣2(I) procollagen gene (COL1A2), leading to the production of collagen, the major structural component of the extracellular matrix. In contrast to the detailed structural knowledge of TGF-␤ responsive elements in the COL1A2 promoter, little was known about the intracellular signaling mechanisms that enable TGF-␤ to stimulate collagen transcription in vivo and in vitro until recently. Upon phosphorylation by TGF-␤ receptors, Smad2 and Smad3, known as receptor Smads (R-Smads), form heteromeric complexes with co-Smad or Smad4. Co-Smad acts as a convergent node in the Smad pathways downstream of TGF-␤ receptors, forming a complex with Smad2 and Smad3. The Smad2-Smad3-Smad4 complex then is translocated into the nucleus, where it functions as a transcription factor, binding DNA either directly or in association with other DNA proteins. [22] [23] 33 The transcriptional role of Smad proteins in collagen production by fibroblasts in relation to fibrosis pathogenesis was demonstrated recently by Chen et al., 26, 27 who directly correlated Smad3 with the transactivation of a chloramphenicol acetyltransferase reporter gene driven by a 772-bp segment of the human COL1A2 promoter containing the putative TGF-␤ response elements. In these experiments, 26, 27 Smad3 mutant harboring substitutions that replaced critical serine residues with alanine abrogated the stimulation of COL1A2 promoter activity by TGF-␤. These data further implicated Smad3 as an important component of TGF-␤ signaling.
The mechanism by which collagen transcription is stimulated by Smad3 recently has been elucidated further by a number of researchers. These researchers showed that Smad3 functionally or synergistically cooperates with the transcription factors of p300/CBP, Sp1 in human fibroblasts, glomer- The data from the current study directly support the hypothesis that TGF-␤/Smad signaling has a role in keloid pathogenesis. 32 Taken together, recent studies strongly suggest a correlation among TGF-␤ receptor, Smad activity, and fibroblast overproliferation and collagen production that leads to abnormal scar formation and pathologic fibrogenesis. The TGF-␤ receptors and Smads therefore represent a potential drug target for scar reduction therapy. Blocking of the TGF-␤/ Smad signaling pathway could theoretically suppress overproliferation of scar fibroblasts and the production of collagen, thus preventing the formation of keloid and hypertrophic scars.
The authors' previous studies have shown that quercetin can inhibit scar-derived fibroblast proliferation, contraction, and production of collagen. 42 An important potential profibrotic mechanism successfully inhibited by quercetin was the IGF-I-signaling pathway. 43 The current study has shown that quercetin also significantly suppresses TGF-␤/Smad signaling in keloid fibroblasts at the concentrations found to be effectively inhibitory to fibroblast proliferation, collagen production, and lattice contraction. 42, 43 Western blot analysis of the TGF-␤ type 1 and type 2 receptors showed that quercetin reduced expression of TGF-␤ receptors in keloid fibroblast cell culture. Analysis of the protein levels of Smad2, Smad3, and Smad4 reinforced this finding by showing that quercetin strongly suppresses the expression of these proteins in keloid fibroblasts and also blocks phosphorylation of Smad2 and Smad3.
Together, these data suggest that quercetin negatively regulates TGF-␤/Smad signaling in keloid fibroblasts at the receptor level and also inhibits its downstream signaling molecules. In the immunoprecipitation experiments, quercetin totally blocked binding of Smad2, Smad3, and Smad4, with no evidence of Smad2 and Smad4 expressions in complexes immunoprecipitated with Smad3 in keloid fibroblasts treated with the compound. On the other hand, quercetin strongly prevented formation of the Smad2-Smad3-Smad4 complex and nuclear translocation. Finally, quercetin also reduced protein levels of p300 and CBP, which are important for the stimulation of endogenous type 1 collagen gene expression and for the enhancement of Smad activity.
In conclusion, this study demonstrated that quercetin effectively blocks the TGF-␤-signaling pathway. Figure 5 summarizes the hypothesized potential of quercetin's mode of action against abnormal scar formation. 
